Finerenone in Persons with Chronic Kidney Disease without Diabetes.
- 22 cites
Finerenone slows kidney function decline and reduces cardiovascular and kidney events in adults with CKD without diabetes, with a significant eGFR preservation over 32 months.
- Why it matters: CKD patients without diabetes lack effective treatments to prevent progression and cardiovascular complications, creating a critical need for targeted therapies.
- What they did: A randomized trial assigned 1,584 adults with CKD but no diabetes to receive finerenone (10 or 20 mg daily) or placebo, measuring eGFR decline and adverse events over 32 months.
- The result: Finerenone resulted in a slower eGFR decline (-3.3 vs. -4.0 ml/min/1.73 m²/year, P<0.001) and lowered the risk of composite kidney or cardiovascular events (hazard ratio 0.77), though hyperkalemia was a common side effect.